ArticleAnnals of medicine2025
Evaluating the expression level of serum Interleukin-2, lipoarabinomannan and circulating MicroRNA-29a as diagnostic biomarkers for pulmonary and extra-pulmonary tuberculosis: a pilot study.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Type 2 diabetes mellitus associated microRNAs in tuberculosis susceptibility: a systematic review and bioinformatic analysis.Frontiers in endocrinology · 2026Pooled it
- Diagnostic and prognostic value of deregulated miR-6822-3p in patients with severe pneumonia.BMC immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiagnosis and treatment of Tuberculosis (TB), particularly delay in diagnosis of TB poses significant challenges in its eradication. The exploration of new biomarkers is urgently required for TB diagnosis and treatment. This study aimed to investigate the serum levels of Interleukin-2 (IL-2), an important diagnostic parameter in TB; lipoarabinomannan (LAM), a key constituent of the mycobacterial cell wall; and the expression of circulating microRNA-29a (miR-29a) in serum. MiR-29a contributes to increased susceptibility to TB by downregulating interferon-γ expression in T cells through post-transcriptional regulation, thereby exerting an immunosuppressive effect. MATERIALS AND
methodsThe study was conducted on pulmonary TB (PTB), extra-pulmonary TB (EPTB), and control groups. Serum from the three groups was isolated, and IL-2 and LAM levels were measured by ELISA. Additionally, q-RT-PCR was conducted to analyse the expression of microRNA-29a in the serum of some TB patients.
resultLAM and IL-2 were significantly upregulated in serum samples from both the PTB and EPTB groups compared to the control group. Additionally, the expression of miR-29a was significantly elevated in the EPTB group.
conclusionThis study suggests that LAM and IL-2 may be potential diagnostic biomarkers for both PTB and EPTB, while miR-29a may be a promising marker specifically for EPTB. However, further evaluation with larger cohort samples is required to validate the clinical utility of LAM, IL-2, and miR-29a as diagnostic TB markers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.